Methylphenidate HCl: therapy for attention deficit hyperactivity disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood. The compound is a piperidine and the D-threo-isomer is considered the biologically active form. The compound is available in multiple short- and long-acting preparations, having different delivery systems leading to varying kinetics without clear superiority in efficacy or tolerability at the group level. Common adverse effects are insomnia, appetite disturbance, stomach ache, headache and dizziness. Its mechanism of action is linked to the monoamines dopamine and norepinephrine. The compound appears to predominantly increase the synaptic concentration of dopamine, presumably via inhibition of the dopamine transporter DAT1. There also appears to be effects on presynaptic vesicular trafficking and distribution of dopamine. Both immediate- and sustained-release preparations of methylphenidate have proven efficacy in children and adults with attention deficit hyperactivity disorder. Analysis of the National Institutes of Health-sponsored multimodal treatment study of attention deficit hyperactivity disorder supports a combined medication and behavioral therapy approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684
MTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
Treatment of ADHD in children with tics: A randomized controlled trial
The Tourette’s Syndrome Study Group (2002) · Neurology · doi:10.1212/wnl.58.4.527 · Cited by 504
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385
GREENHILL, L. L., SWANSON, J. M., VITIELLO, B., DAVIES, M., CLEVENGER, W., WU, M., ARNOLD, L. E., ABIKOFF, H. B., BUKSTEIN, O. G., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00012 · Cited by 287
Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder
BARRICKMAN, L. L., PERRY, P. J., ALLEN, A. J., KUPERMAN, S., ARNDT, S. V., HERRMANN, K. J., & SCHUMACHER, E. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00017 · Cited by 254
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238
Placebo-Controlled Evaluation of Ritalin Side Effects
Ahmann, P. A., Waltonen, S. J., Theye, F. W., Olson, K. A., & Van Erem, A. J. (1993) · Pediatrics · doi:10.1542/peds.91.6.1101 · Cited by 178
Mattay, V. S., Berman, K. F., Ostrem, J. L., Esposito, G., Van Horn, J. D., Bigelow, L. B., & Weinberger, D. R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-15-04816.1996 · Cited by 151
Cited by
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102
“Methylphenidate (MPH; marketed under trade names ConcertaH MetadateH, MethylinH, RitalinH) is one of the most commonly prescribed stimulant medications for the symptomatic management of ADHD and narcolepsy [1,2,3].”
BackgroundEmergence of Tics in Children with ADHD: Impact of Once-Daily OROS® Methylphenidate Therapy
Palumbo, D., Spencer, T., Lynch, J., Co-Chien, H., & Faraone, S. V. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649138 · Cited by 67
Effects of Once-Daily Oral and Transdermal Methylphenidate on Sleep Behavior of Children With ADHD
Faraone, S. V., Glatt, S. J., Bukstein, O. G., Lopez, F. A., Arnold, L. E., & Findling, R. L. (2009) · Journal of Attention Disorders · doi:10.1177/1087054708314844 · Cited by 56
Zhang, C.-L., Feng, Z.-J., Liu, Y., Ji, X.-H., Peng, J.-Y., Zhang, X.-H., Zhen, X.-C., & Li, B.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051910 · Cited by 41
“Interestingly in a recent report, mice mutant with one subtype of the DGK, DGKb, have been shown to express various dysfunctions similar with ADHD symptoms.”
BackgroundInfluentialEffect of Methylphenidate on Sleep Parameters in Children with ADHD
Lee, S. H., Seo, W. S., Sung, H. M., Choi, T. Y., Kim, S. Y., Choi, S.-J., Koo, B. H., & Lee, J. H. (2012) · Psychiatry Investigation · doi:10.4306/pi.2012.9.4.384 · Cited by 30
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26
“It inhibits the transporters of these neurotransmitters, resulting in an increase in dopamine and adrenaline levels in the synaptic cleft (67).”
Background
Metadata
- Authors
- Capp, P. K., Pearl, P. L., & Conlon, C.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2005-05
- Volume
- 5
- Issue
- 3
- Pages
- 325-331
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2140918476
- Cited by
- 40
- References
- 13
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.